These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8398824)

  • 21. No correlation between response and survival in patients with multiple myeloma treated with vincristine, melphalan, cyclophosphamide, and prednisone.
    Baldini L; Radaelli F; Chiorboli O; Fumagalli S; Cro L; Segala M; Cesana BM; Polli EE; Maiolo AT
    Cancer; 1991 Jul; 68(1):62-7. PubMed ID: 2049754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.
    Shimizu K; Kamiya O; Hamajima N; Mizuno H; Kobayashi M; Hirabayashi N; Takeyama H; Kato R; Kawashima K; Nitta M
    Jpn J Cancer Res; 1990 Dec; 81(12):1320-7. PubMed ID: 2126002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of multiple myeloma using vincristine, cyclophosphamide, melphalan and prednisone (VCMP). Long-term results in 63 patients].
    Bladé J; Urbano A; López Guillermo A; Rozman M; Rovira M; Montserrat E; Rozman C
    Sangre (Barc); 1990 Apr; 35(2):93-7. PubMed ID: 2363100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma.
    McCloskey EV; Dunn JA; Kanis JA; MacLennan IC; Drayson MT
    Br J Haematol; 2001 Jun; 113(4):1035-43. PubMed ID: 11442499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum thymidine kinase activity in clinically healthy and diseased cats: a potential biomarker for lymphoma.
    Taylor SS; Dodkin S; Papasouliotis K; Evans H; Graham PA; Belshaw Z; Westberg S; von Euler HP
    J Feline Med Surg; 2013 Feb; 15(2):142-7. PubMed ID: 23076596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.
    Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA
    Med Oncol; 2002; 19(4):219-26. PubMed ID: 12512915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow histology and serum beta 2 microglobulin in multiple myeloma--a new prognostic strategy.
    Bartl R; Frisch B; Diem H; Mündel M; Fateh-Moghadam A
    Eur J Haematol Suppl; 1989; 51():88-98. PubMed ID: 2697597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma.
    Larsdotter S; Nostell K; von Euler H
    Vet J; 2015 Aug; 205(2):313-6. PubMed ID: 25744802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma.
    Pavlovsky S; Saslavsky J; Tezanos Pinto M; Palmer L; Curuchet M; Lein JM; Garay G; Dragosky M; Quiroga-Micheo E; Huberman AB
    J Clin Oncol; 1984 Jul; 2(7):836-40. PubMed ID: 6376722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IgD multiple myeloma. A report of three cases.
    Martini R; Santini S; Bottari G
    Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Myelomatosis. A study of 138 patients treated with melphalan, prednisone and vincristine with particular attention to the prognostic value of a stage subdivision].
    Johnsen HE; Bergmann OJ; Boesen AM; Pedersen BB; Ellegaard J; Bastrup-Madsen P
    Ugeskr Laeger; 1989 Mar; 151(13):816-21. PubMed ID: 2718264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuous low dose of melphalan and prednisone in patients with multiple myeloma of very old age or severe associated disease.
    Pulsoni A; Villivà N; Cavalieri E; Falcucci P; La Verde G; Matera R; Petrucci MT; Tosti ME; Mandelli F
    Drugs Aging; 2002; 19(12):947-53. PubMed ID: 12495369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melphalan and prednisone (MP) versus vincristine, BCNU, adriamycin, melphalan and dexamethasone (VBAMDex) therapy for multiple myeloma. Early results of a multicenter trial. The German Myeloma Treatment Group.
    Peest D; Deicher H; Coldewey R; von Broen IM; Cammerer U; Hein R; Hoffmann L; Konyar H; Kreuser ED; Selbach J
    Onkologie; 1990 Feb; 13(1):43-4. PubMed ID: 2186324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Coleman M; Cooper MR; Henderson E
    J Clin Oncol; 1988 Sep; 6(9):1481-90. PubMed ID: 3047338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conventional induction treatments do not influence overall survival in multiple myeloma.
    Boccadoro M; Palumbo A; Argentino C; Dominietto A; Frieri R; Avvisati G; Comotti B; Lauta VM; Liberati M; Marmont F; Musto P; Tribalto M; Pileri A
    Br J Haematol; 1997 Feb; 96(2):333-7. PubMed ID: 9029022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.